

Supplemental Table 1. Therapeutic strategies and response after relapse

	Total	t(8;21)	inv(16)
	N=139	N=92	N=47
Re-induction chemotherapy			
None, n (%)	6 (4)	5 (5)	1 (2)
Standard-dose cytarabine-based, n (%)	92 (66)	57 (62)	35 (74)
High-dose cytarabine-based, n (%)	29 (21)	22 (24)	7 (15)
Less-intensive chemotherapy, n (%)	12 (9)	8 (9)	4 (9)
Remission after first re-induction therapy			
Yes, n (%)	85 (61)	48 (52)	37 (79)
No, n (%)	54 (39)	44 (48)	10 (21)
Consolidation chemotherapy after relapse			
None, n (%)	33 (24)	22 (24)	11 (23)
Including high-dose cytarabine-based, n (%)	49 (35)	33 (36)	16 (34)
Standard-dose cytarabine-based, n (%)	48 (35)	31 (34)	17 (36)
Others, n (%)	9 (6)	6 (7)	3 (6)
Number of consolidation chemotherapy			
1 course, n (%)	40 (29)	26 (28)	14 (30)
2 courses, n (%)	29 (21)	20 (22)	9 (19)
3 courses, n (%)	19 (14)	15 (16)	4 (9)
4 courses, n (%)	18 (13)	9 (10)	9 (19)
Eventual achievement of CR2			
Yes, n (%)	98 (71)	58 (63)	40 (85)
No, n (%)	41 (29)	34 (37)	7 (15)
Autologous HCT			
Yes, n (%)	6 (4)	5 (5)	1 (2)
No, n (%)	133 (96)	87 (95)	46 (98)
Allogeneic HCT			
Yes, n (%)	96 (69)	65 (71)	31 (66)
No, n (%)	43 (31)	27 (29)	16 (34)

CR2: second complete remission; HCT: hematopoietic cell transplantation